Table 1.
Overview of the studies with and without bevacizumab in ovarian cancer.
| Study Name Author, Year [Ref] |
Study Population, Number |
Regimen | mPFS (Months) p Value |
mOS (Months) p Value |
VTE n/N (%) |
ATE n/N (%) |
|---|---|---|---|---|---|---|
| GOG-0218 Tewari, 2018 [16] |
Frontline stage III (incomplete resection) and stage IV (all) N = 1873 |
A: C + P + pbo x6 B: C + P + bev x6 C: C + P + bev x6 → bev x16 |
A: 10.3 m B: 11.3 m C: 14.1 m |
A: 41.1 m B: 40.8 m C: 43.3 m |
A: 35/601 (5.8%) B: 36/607 (5.9%) C: 42/608 (6.9%) |
A: 5/601 (0.7%) B: 4/607 (0.7%) C: 4/608 (0.7%) |
| ICON-7 Perren, 2011 [17] |
Frontline stage I-IIa (high risk) OR stage IIb-IV N = 1498 |
A: C + P + pbo x6 → pbo x10 B: C + P + bev1 x6 → bev1 x10 |
A: 17.5 m B: 19.9 m |
A: 58.6 m B: 58.0 m |
A: 31/753 (4.1%) B: 50/745 (6.7%) |
A: 11/753 (1.4%) B: 27/745 (3.6%) |
| ANTHALYA Joly, 2017 [33] |
Frontline stage IIIc-IV neoadjuvant N = 99 |
A: C + P x4 → IDS → C + P + bev x1 → bev x16 B:(C + P) x4 + bev x3 →IDS →(C + P) x2 + bev x1 → bev x16 |
A: 21.2 m [14.5–26.7] B: 23.5 m [18.5–30.6] |
NA | A: 2/37 (5%) B: 6/58 (11%) |
NA |
| GEICO-1205 Garcia-Garcia, 2019 [34] |
Frontline FIGO IIIc-IV OC neoadjuvant N = 68 |
A: C + P x4 → IDS →C + P + bev x3 → bev x15 B: C + P + bev x4 → IDS → C + P + bev x3 → bev x15 |
A: 20.1 m B: 20.4 m |
NA | A: 0/33 (0%) * B: 2/35 (5.7%) * |
NA |
| mEOC/GOG0421 Gore, 2019 [35] |
Frontline mucinous stage II-IV or relapsed stage I N = 50 |
A: C + P x6 vs. B: Ox + Cap x6 vs. C: C + P + Bev x6 → bev x12 vs. D: Ox + Cap + Bev x6 → bev x12 |
A&B: 8.1 m C&D: 18.1 m |
A&B: 32.7 m C&D: 27.7 m |
A&B: 0/26 (0%) * C&D:1/24 (4.1%) * |
NA |
| Zhang, 2020 [36] | Frontline stage I-III N = 100 |
A: C B: Npl85 + bev1 |
A: NA B: NA |
A: NA B: NA |
A: NA B: NA |
A: NA B: NA |
| OCEANS Aghajanian, 2015 [20] |
Relapsed platinum-sensitive N = 484 |
A: C + G + pbo x6 B: C + G + bev x6 → bev maintenance |
A: 8.4 m B: 12.4 m |
A: 32.9 m B: 33.6 m |
A: 6/233 (2.6%) * B:11/247 (4.5%) * |
A: 1/233 (0.4%) B: 6/247 (2.4%) |
| GOG-0213 Coleman, 2017 [21] |
Relapsed platinum-sensitive N = 674 |
A: C + P B: C + P + bev x6 → bev maintenance *** |
A: 10.4 m B: 13.8 m |
A: 37.3 m B: 42.2 m |
A: 0/327 (0%) B: 0/330 (0%) |
A: 6/327 (1.8%) B: 22/330 (6.6%) |
| MITO16B-MaNGO OV2B-ENGOT OV17 Pignata, 2021 [37] |
Relapsed platinum sensitive, prior bevacizumab N = 406 |
A: C + P or C + G or C + PLD B: C + P or C + G or C + PLD + bev2 |
A: 8.8 m B: 11.8 m |
A: 27.1 m B: 26.7 m |
NA ** | NA ** |
| NSGO-AVANOVA2/ ENGOT-OV24 Mirza, 2019 [38] |
Relapsed platinum sensitive N = 97 |
A: niraparib B: niraparib + bev |
A: 5.5 m B: 11.9 m |
NA | A: 1/48 (2.2%) B: 2/49 (4.2%) |
NA |
| Cong, 2019 [39] | Relapsed platinum sensitive N = 164 |
A: C + P B: C + P + bev2 |
A: 6.7 m B: 9.3 m |
A: 12.5 m B: 18.5 m |
NA | NA |
| AURELIA Pujade-Lauraine, 2014 [22] |
Relapsed platinum resistant N = 360 |
A: wP or Tp or PLD B: wP or Tp or PLD + bev |
A: 3.4 m B: 6.7 m |
A: 13.3 m B: 16.6 m |
A: 8/181 (4.4%) * B: 5/179 (2.8%) * |
A: 0/181 (0%) B: 4/179 (2.2%) |
| Liu, 2019 [41] | Relapsed platinum resistant N = 86 |
A: ABP B: ABP + bev1 |
A: 6.7 m B: 8.9 m |
A: 12.7 m B: 16.3 m |
NA | NA |
| Zhang, 2019 [40] | Relapsed platinum sensitive N = 160 |
A: DTx + Npl80 B: DTx + Npl80 + bev1 |
A: 8.6 m B: 12.2 m |
A: 17.7 m B: 22.5 m |
NA | NA |
ABP: albumin-bound paclitaxel 135–175 mg/m2 Q3w x6; ATE: arterial thromboembolic events; bev = bevacizumab 15 mg/kg IV Q3w; bev1 = bevacizumab 7.5 mg/kg IV Q3w; bev2 = bevacizumab 10 mg/kg IV Q2w or 15 mg/kg Q3w; C: carboplatin 400 mg/m2 Q3w x3; C + G: Carboplatin AUC4 Q3w + gemcitabin 1250 mg/m2 d1 + 8; C + P: carboplatin AUC5-6 Q3w + paclitaxel 175 mg/m2 Q3w x6; C + PLD: carboplatin AUC5 + pegylated liposomal doxorubicin 30 mg/m2 Q4w; DTX: Docetaxel 75 mg/m2; PLD: pegylated liposomal doxorubicin 40 mg/m2 Q4w; IDS: interval debulking surgery; mPFS: median progression-free survival expressed in months; mOS: median overall survival expressed in months; NA: not available; Npl80: nedaplatin 80 mg/m2 Q3w; Npl85: nedaplatin 85 mg/m2 Q3w x6; niraparib: 300 mg once daily; Ox-Cap: oxaliplatin 130 mg/m2 intravenous d1 Q2w + capecitabine 850 mg/m2 orally bid d1–14; pbo: placebo; Tp: Topotecan 4 mg/m2 d1–8–15 Q3w; VTE: venous thromboembolism (all grades unless otherwise specified); wP: Paclitaxel 80 mg/m2 d1–8–15–22 Q4w. * Grade ≥ 3 VTE. ** all thromboembolic events: 5/200 (A) vs. 6/200 (B) *** 2 × 2 design: surgery vs. no surgery; bevacizumab vs. no bevacizumab. Data shown with/without bevacizumab. Surgery analysis was done in a separate publication.